Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Budesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | IL5 | P05113 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL16139563 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17168987 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL9763339 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12440030 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19635 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL10020756 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17151422 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17971368 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13918824 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046256-A1 | Lipolytic Methods for Regional Adiposity Comprising Salmeterol or Formoterol | LITHERA, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110105446-A1 | Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment | LITHERA, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7829554-B2 | contacting a targeted fat deposit with a formulation comprising long acting beta-2 adrenergic receptor agonist selected from salmeterol, formoterol and a glucocorticosteroid (e.g. dexamethasone, prednisolone, fluticasone, budesonid), a carrier, a excipient formulated for injection | LITHERA, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100137267-A1 | FORMULATIONS FOR TREATMENT OF ADIPOSE TISSUE, CUTANEOUS TISSUE AND DISORDERS, AND MUSCULAR TISSUE | NEOTHETICS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100119609-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR THE TREATMENT OF THYROID EYE DISEASE | NEOTHETICS, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119609-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR THE TREATMENT OF THYROID EYE DISEASE | TSHR, TRHR, ADRB2 | NR3C1 27/4885PGR 427/4885CYP3A4 2776/4885 |
| US-20120046256-A1 | Lipolytic Methods for Regional Adiposity Comprising Salmeterol or Formoterol | ADRB2, LIPE, ADRB3 | NR3C1 47/4885PGR 1043/4885CYP3A4 1364/4885 |
| US-20100137267-A1 | FORMULATIONS FOR TREATMENT OF ADIPOSE TISSUE, CUTANEOUS TISSUE AND DISORDERS, AND MUSCULAR TISSUE | ADRB2, ADRA2C, ADRA2A | NR3C1 17/4885PGR 574/4885CYP3A4 980/4885 |
| US-20110105446-A1 | Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment | ADRB2, LIPE, ADRA2A | NR3C1 32/4885PGR 416/4885CYP3A4 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.